Clinical development failure or delay
Pipeline value depends on positive trial outcomes for ALXN1840 and MNPR-101 programs.
- Scope
- ALXN1840, MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac225
- Materiality
- High
Monopar Therapeutics
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers. Its pipeline centers on ALXN1840, a late-stage Wilson disease asset, and MNPR-101 radiopharmaceutical programs for imaging and treating solid tumors.
51.35
51.35
| % | |
|---|---|
| Wilson disease therapy | 35% Late-stage investigational treatment for Wilson disease, centered on ALXN1840. |
| Radiopharmaceutical imaging | 25% MNPR-101-based diagnostic imaging and dosimetry programs for advanced cancers. |
| Radiopharmaceutical therapeutics | 25% Therapeutic radioisotope programs designed to treat uPAR-expressing solid tumors. |
| Preclinical pipeline and discovery | 10% Earlier-stage assets and internal R&D to expand the oncology pipeline. |
| Licensing and development services | 5% In-licensing, collaboration, and regulatory development activities supporting the pipeline. |
Monopar does not yet sell approved products, so its near-term customers are clinical investigators, trial sites,...
- Regulators and clinical trial ecosystemprimary
FDA, CROs, and trial sites that enable development and approval of ALXN1840 and MNPR-101 programs.
- Wilson disease treatment providersprimary
Specialist physicians and treatment centers that would prescribe ALXN1840 if approved.
- Advanced cancer care centerssecondary
Hospitals and oncology centers that could use MNPR-101 imaging or therapeutic agents.
- Strategic licensing partnersprimary
Pharma partners that may out-license, co-develop, or commercialize assets with Monopar.
Monopar is headquartered in the United States and its development, financing, and clinical operations are primarily U.S...
- •Headquartered in the United States
- •Clinical trials and regulatory work are primarily U.S.-based
- •NDA filing is being prepared for the FDA
- •Potential future commercialization could expand beyond the U.S.
- •Management has prior FDA and EMA experience
Monopar’s strategy is to advance a small number of high-value assets through late-stage development, starting with an...
01
Prepare ALXN1840 NDA submissionshort-term
Regulatory approval is the key value inflection point for the Wilson disease asset.
02
Advance MNPR-101 radiopharmaceutical pipelinemedium-term
The imaging and therapeutic programs could create a second value driver in oncology.
03
Preserve financing flexibilityshort-term
As a pre-revenue biotech, Monopar must fund R&D until approval or partnering monetization.
Monopar is a pre-revenue biotech, so its business depends on successful clinical development, regulatory approval, and...
Financing and dilution risk
The company has not generated product revenue and expects to fund operations externally.
- Scope
- Equity raises, debt, collaborations, grants
- Materiality
- High
Regulatory approval risk
Commercialization depends on FDA approval of a late-stage rare disease asset and oncology candidates.
- Scope
- NDA filing for ALXN1840
- Materiality
- High
Competition and market adoption risk
Competing therapies could limit uptake or reduce the commercial potential of the pipeline.
- Scope
- Wilson disease and oncology markets
- Materiality
- Medium
Manufacturing and supply chain risk
Radiopharmaceutical and clinical supply chains are complex and must meet quality standards.
- Scope
- Clinical and future commercial supply
- Materiality
- Medium
Clinical trial accruals
Can cause quarter-to-quarter swings in R&D expense
Stock-based compensation
Can inflate non-cash operating expenses
Treasury securities and interest income
Affects net loss and liquidity presentation
Equity financing and share issuance
Changes share count and cash runway
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Allarity Therapeutics, Inc.
ALLR · Pharmaceutical Preparations
Cullinan Therapeutics, Inc.
CGEM · Biological Products, (No Diagnostic Substances)
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Eledon Pharmaceuticals, Inc.
ELDN · Pharmaceutical Preparations
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
: 28/04/2026